Health-related Quality of Life and Neurocognitive Functioning After Glioblastoma Treatment
Introduction With a median survival of 12 to 14 months, the prognosis of patients with glioblastoma multiforme (GBM) remains poor. Treatment is therefore not only designed to prolong survival but also…